- Home
- VTYX vs CAAS Comparison
VTYX vs CAAS Comparison
Compare VTYX & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- CAAS
- Stock Information
- Founded
- VTYX 2018
- CAAS N/A
- Country
- VTYX United States
- CAAS China
- Employees
- VTYX N/A
- CAAS N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- CAAS Auto Parts:O.E.M.
- Sector
- VTYX Health Care
- CAAS Consumer Discretionary
- Exchange
- VTYX Nasdaq
- CAAS Nasdaq
- Market Cap
- VTYX 154.9M
- CAAS 130.9M
- IPO Year
- VTYX 2021
- CAAS N/A
- Fundamental
- Price
- VTYX $2.58
- CAAS $3.93
- Analyst Decision
- VTYX Buy
- CAAS
- Analyst Count
- VTYX 4
- CAAS 0
- Target Price
- VTYX $11.33
- CAAS N/A
- AVG Volume (30 Days)
- VTYX 1.1M
- CAAS 29.3K
- Earning Date
- VTYX 08-15-2025
- CAAS 08-13-2025
- Dividend Yield
- VTYX N/A
- CAAS N/A
- EPS Growth
- VTYX N/A
- CAAS N/A
- EPS
- VTYX N/A
- CAAS 0.96
- Revenue
- VTYX N/A
- CAAS $678,635,000.00
- Revenue This Year
- VTYX N/A
- CAAS N/A
- Revenue Next Year
- VTYX N/A
- CAAS N/A
- P/E Ratio
- VTYX N/A
- CAAS $4.24
- Revenue Growth
- VTYX N/A
- CAAS 18.33
- 52 Week Low
- VTYX $0.78
- CAAS $3.34
- 52 Week High
- VTYX $3.39
- CAAS $5.37
- Technical
- Relative Strength Index (RSI)
- VTYX 46.35
- CAAS 37.54
- Support Level
- VTYX $2.63
- CAAS $4.00
- Resistance Level
- VTYX $2.92
- CAAS $4.23
- Average True Range (ATR)
- VTYX 0.22
- CAAS 0.14
- MACD
- VTYX -0.08
- CAAS -0.03
- Stochastic Oscillator
- VTYX 0.00
- CAAS 11.32
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.